The National Medical Products Administration (NMPA) has announced the priority review approval for Roche Diagnostics GmbH under its Priority Approval Procedure for Medical Devices (2016 No. 168).

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

A respected organization acclaimed for their groundbreaking work with neurological diseases, C2N Diagnostics, LLC, is partnering with The Michael J. Fox Foundation For Parkinson’s Research (MJFF) to better understand the connections amongst neurodegenerative conditions, Alzheimer’s disease (AD) and neuronal a-synuclein disease (NSD), which encompasses Parkinson’s disease (PD), Lewy body dementia (LBD) and REM behavior disorder (RBD).

The Davos Alzheimer's Collaborative (DAC) announced on Wednesday that it is partnering with Janssen Research & Development and Danaher subsidiary Beckman Coulter Diagnostics to validate blood-based biomarkers for Alzheimer's disease.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.

Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, announced new data demonstrating that the company’s blood-biomarker alpha synuclein (α-synuclein) signatures accurately detect the aggregation of α-synuclein in the brain from a simple blood draw. Results from the study, which will be shared in a poster presentation (#116) on October 31 at the Clinical Trials on Alzheimer’s Disease (CTAD) international conference, demonstrate that Sunbird’s technology could provide blood-based diagnosis of multiple neurodegenerative diseases, including Parkinson’s disease, with high accuracy.

Massachusetts and Singapore-based biotechnology company Sunbird Bio has raised $14m to advance the clinical development of its blood-based diagnostic platform for neurological disorders and early-stage cancer.

An international team has tracked the protein changes that occur in cerebrospinal fluid (CSF) during disease progression in individuals with autosomal dominant forms of Alzheimer's disease.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a collaboration with Eli Lilly and Company to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes which can play a role in the diagnosis of Alzheimer’s disease. This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping.